These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Deep-vein thrombosis in malignancy: how long should patients be treated, and with what?
    Author: Merli GJ.
    Journal: Catheter Cardiovasc Interv; 2009 Jul 01; 74 Suppl 1():S27-34. PubMed ID: 19530157.
    Abstract:
    Cancer patients are at high-risk of venous thromboembolism (VTE). However, the optimal VTE prophylaxis and treatment options for this population are currently unclear. Surgical cancer patients have been shown to benefit from pharmacological VTE prophylaxis, with a number of trials suggesting that prophylaxis duration should extend beyond the traditional 7 day period. Medical (nonsurgical) cancer patients are also at high-risk of VTE, and evidence-based guidelines recommend pharmacological VTE prophylaxis in hospitalized cancer patients who are bedridden. In cancer patients with confirmed VTE, questions remain over the most effective long-term treatment regimen. Further trials are required to help physicians to make evidence-based choices for the management of VTE in these patients.
    [Abstract] [Full Text] [Related] [New Search]